Search

Search Constraints

You searched for: Author/Creator Joseph‐Mathurin, Nelly

Search Results

1. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance. (31st December 2021)

2. [IC‐P‐057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. (1st July 2017)

3. [IC‐P‐166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. (1st July 2017)

4. [O1–02–04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. (1st July 2017)

5. [P2–372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. (1st July 2017)

6. AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (20th December 2022)

7. AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (20th December 2022)

8. Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Issue 5 (13th October 2022)

9. Biomarker clustering in autosomal dominant Alzheimer's disease. Issue 1 (1st April 2022)

10. Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial. (31st December 2021)